Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

FNZ employee shareholders told success more likely
Finance

FNZ employee shareholders told success more likely

Account show loss at global fintech widens. 

Victoria Young 05 Jun 2025
NZ Super ahead of the curve on US equities
Finance

NZ Super ahead of the curve on US equities

New Zealand’s sovereign wealth fund has been overweight in European equities.

Gregor Thompson 03 Jun 2025
Former Telecom chair Wayne Boyd honoured
Finance

Former Telecom chair Wayne Boyd honoured

Honours recognition for a lifetime of low-key, high-quality leadership.

Pattrick Smellie 02 Jun 2025
Andrew Barclay to leave Goldman Sachs NZ
Finance

Andrew Barclay to leave Goldman Sachs NZ

Andrew Barclay has been one of NZ’s most respected deal-makers.

Pattrick Smellie 20 May 2025